Posted 12 November 2019
As cannabis scripts continue their dramatic rise, policy makers and members of the burgeoning industry will gather in Melbourne next March at a conference developed by newly established industry body Medicinal Cannabis Industry Australia (MCIA).
The body announced the inaugural conference 'ACannabis' event will include policy makers, government, healthcare professionals (HCPs), cultivators, manufacturers, businesses, patients and industry.
"ACannabis is the platform to gain a deep understanding of ground-breaking research, an inside perspective on global trends and a unique opportunity for the agritech and medtech sector to have the conversations required to leverage out advantages," MCIA chair and Cann Group CEO Peter Crock said.
It comes as the medicinal cannabis industry shows no sign of slowing down locally and overseas, with Cann Group recently signing a distribution deal with Symbion.
The company signed the deal with the wholesaler last week in hopes of launching its first locally manufactured products in the first quarter of 2020.
It has also signed a local manufacturing deal with IDT Australia and is in the middle of expanding an $11 million facility it has in Victoria.
These products will be made accessible to patients via the current Special Access Scheme (SAS), which is overseen by the TGA.
Patients accessing the therapies have increased, with scripts skyrocketing over the past 12 months and increasing month-on-month. The most recent figures for October show SAS approvals at 3,594, taking the annual total for 2019 to 18,000 to date.
In August, the government agreed to reduce red tape restricting access to the therapies including establishing a single licence model for suppliers and makers.